Health Canada issues revised guidance on interpretation of a significant change to a device
This article was originally published in RAJ Devices
Executive Summary
Health Canada has issued revised guidance on the interpretation of a significant change to a class III or IV (medium-high and highest-risk) medical device that would require a manufacture to apply for an amended product licence1,2.
You may also be interested in...
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.
EMA Presses On With Keenly-Awaited Guidance On How To Use Patient Experience Data
While the International Council of Harmonisation is developing a harmonized approach to patient-focused drug development, the European Medicines Agency has heeded calls for “prompt guidance” to support the systematic inclusion of patient experience data in regulatory submissions.